225 related articles for article (PubMed ID: 29996796)
1. Association between low bone mass and the serum RANKL and OPG in patients with nephrolithiasis.
Mansour A; Aboeerad M; Qorbani M; Hashemi Taheri AP; Pajouhi M; Keshtkar AA; Larijani B; Mohajeri-Tehrani MR; Ganji MR
BMC Nephrol; 2018 Jul; 19(1):172. PubMed ID: 29996796
[TBL] [Abstract][Full Text] [Related]
2. Higher levels of s-RANKL and osteoprotegerin in children and adolescents with type 1 diabetes mellitus may indicate increased osteoclast signaling and predisposition to lower bone mass: a multivariate cross-sectional analysis.
Tsentidis C; Gourgiotis D; Kossiva L; Doulgeraki A; Marmarinos A; Galli-Tsinopoulou A; Karavanaki K
Osteoporos Int; 2016 Apr; 27(4):1631-1643. PubMed ID: 26588909
[TBL] [Abstract][Full Text] [Related]
3. Relationships among serum receptor of nuclear factor-kappaB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatory.
Nabipour I; Larijani B; Vahdat K; Assadi M; Jafari SM; Ahmadi E; Movahed A; Moradhaseli F; Sanjdideh Z; Obeidi N; Amiri Z
Menopause; 2009; 16(5):950-5. PubMed ID: 19387415
[TBL] [Abstract][Full Text] [Related]
4. Osteoprotegerin and RANKL in the pathogenesis of rheumatoid arthritis-induced osteoporosis.
Xu S; Wang Y; Lu J; Xu J
Rheumatol Int; 2012 Nov; 32(11):3397-403. PubMed ID: 22057136
[TBL] [Abstract][Full Text] [Related]
5. The sex-specific association of serum osteoprotegerin and receptor activator of nuclear factor kappaB legend with bone mineral density in older adults: the Rancho Bernardo study.
Stern A; Laughlin GA; Bergstrom J; Barrett-Connor E
Eur J Endocrinol; 2007 May; 156(5):555-62. PubMed ID: 17468191
[TBL] [Abstract][Full Text] [Related]
6. Serum RANKL, osteoprotegerin (OPG) and RANKL/OPG ratio in children with systemic lupus erythematosus.
Ali R; Hammad A; El-Nahrery E; Hamdy N; Elhawary AK; Eid R
Lupus; 2019 Sep; 28(10):1233-1242. PubMed ID: 31403902
[TBL] [Abstract][Full Text] [Related]
7. Elevated serum levels of soluble receptor activator of nuclear factors-kappaB ligand (sRANKL) and reduced bone mineral density in patients with ankylosing spondylitis (AS).
Kim HR; Lee SH; Kim HY
Rheumatology (Oxford); 2006 Oct; 45(10):1197-200. PubMed ID: 16567356
[TBL] [Abstract][Full Text] [Related]
8. RANKL:osteoprotegerin ratio and bone mineral density in children with untreated juvenile dermatomyositis.
Rouster-Stevens KA; Langman CB; Price HE; Seshadri R; Shore RM; Abbott K; Pachman LM
Arthritis Rheum; 2007 Mar; 56(3):977-83. PubMed ID: 17328075
[TBL] [Abstract][Full Text] [Related]
9. Association of genetic polymorphisms of RANK, RANKL and OPG with bone mineral density in Chinese peri- and postmenopausal women.
Shang M; Lin L; Cui H
Clin Biochem; 2013 Oct; 46(15):1493-501. PubMed ID: 23531404
[TBL] [Abstract][Full Text] [Related]
10. Associations between osteoprotegerin and femoral neck BMD in hemodialysis patients.
Doumouchtsis KK; Kostakis AI; Doumouchtsis SK; Tziamalis MP; Stathakis CP; Diamanti-Kandarakis E; Dimitroulis D; Perrea DN
J Bone Miner Metab; 2008; 26(1):66-72. PubMed ID: 18095066
[TBL] [Abstract][Full Text] [Related]
11. Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients.
Dobnig H; Hofbauer LC; Viereck V; Obermayer-Pietsch B; Fahrleitner-Pammer A
Osteoporos Int; 2006; 17(5):693-703. PubMed ID: 16435076
[TBL] [Abstract][Full Text] [Related]
12. Imbalance of osteoprotegerin/receptor activator of nuclear factor-κB ligand and oxidative stress in patients with obstructive sleep apnea-hypopnea syndrome.
Ma XR; Wang Y; Sun YC
Chin Med J (Engl); 2019 Jan; 132(1):25-29. PubMed ID: 30628956
[TBL] [Abstract][Full Text] [Related]
13. Effect of recent spinal cord injury on the OPG/RANKL system and its relationship with bone loss and the response to denosumab therapy.
Gifre L; Ruiz-Gaspà S; Carrasco JL; Portell E; Vidal J; Muxi A; Monegal A; Guañabens N; Peris P
Osteoporos Int; 2017 Sep; 28(9):2707-2715. PubMed ID: 28580511
[TBL] [Abstract][Full Text] [Related]
14. Circulating levels of osteoprotegerin and receptor activator of NF-kappaB ligand in patients with chronic renal failure.
Shaarawy M; Fathy SA; Mehany NL; Hindy OW
Clin Chem Lab Med; 2007; 45(11):1498-503. PubMed ID: 17970704
[TBL] [Abstract][Full Text] [Related]
15. Serum osteoprotegerin and its ligand in cirrhotic patients referred for orthotopic liver transplantation: relationship with metabolic bone disease.
Monegal A; Navasa M; Peris P; Alvarez L; Pons F; Rodés J; Guañabens N
Liver Int; 2007 May; 27(4):492-7. PubMed ID: 17403189
[TBL] [Abstract][Full Text] [Related]
16. Maintained malnutrition produces a progressive decrease in (OPG)/RANKL ratio and leptin levels in patients with anorexia nervosa.
Muñoz-Calvo MT; Barrios V; García de Alvaro MT; Lefort M; Méndez-Dávila C; Argente J; de la Piedra C
Scand J Clin Lab Invest; 2007; 67(4):387-93. PubMed ID: 17558893
[TBL] [Abstract][Full Text] [Related]
17. Relationships between OPG, RANKL, bone metabolism, and bone mineral density in biliary atresia.
Honsawek S; Chaiwatanarat T; Vejchapipat P; Chongsrisawat V; Thawornsuk N; Poovorawan Y
Pediatr Surg Int; 2009 Mar; 25(3):261-7. PubMed ID: 19184056
[TBL] [Abstract][Full Text] [Related]
18. Increased serum osteoprotegerin in patients with primary adrenal insufficiency receiving conventional hydrocortisone substitution.
Fichna M; Zurawek M; Fichna P; Gryczynska M; Nowak J; Ruchala M
J Physiol Pharmacol; 2012 Dec; 63(6):677-82. PubMed ID: 23388484
[TBL] [Abstract][Full Text] [Related]
19. Relationships between insulin-like growth factor-I (IGF-I) and OPG, RANKL, bone mineral density in healthy Chinese women.
Zhao HY; Liu JM; Ning G; Zhao YJ; Chen Y; Sun LH; Zhang LZ; Xu MY; Chen JL
Osteoporos Int; 2008 Feb; 19(2):221-6. PubMed ID: 17703270
[TBL] [Abstract][Full Text] [Related]
20. Associations of Bone Mineral Density with RANKL and Osteoprotegerin in Arab Postmenopausal Women: A Cross-Sectional Study.
Amer OE; Wani K; Ansari MGA; Alnaami AM; Aljohani N; Abdi S; Hussain SD; Al-Daghri NM; Alokail MS
Medicina (Kaunas); 2022 Jul; 58(8):. PubMed ID: 35893092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
